Osterweis Capital Management Inc. Purchases New Holdings in AtriCure, Inc. $ATRC

Osterweis Capital Management Inc. acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 501,355 shares of the medical device company’s stock, valued at approximately $14,028,000. Osterweis Capital Management Inc. owned approximately 0.99% of AtriCure at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Legal & General Group Plc bought a new position in shares of AtriCure during the second quarter valued at approximately $1,116,000. The Manufacturers Life Insurance Company purchased a new position in shares of AtriCure during the second quarter valued at approximately $699,000. Paradigm Capital Management Inc. NY bought a new stake in shares of AtriCure in the 2nd quarter worth approximately $3,444,000. Sanctuary Advisors LLC bought a new stake in shares of AtriCure in the 2nd quarter worth approximately $490,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of AtriCure in the 2nd quarter worth approximately $9,388,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

ATRC has been the subject of a number of analyst reports. BTIG Research raised their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday. Raymond James Financial set a $52.00 target price on AtriCure in a report on Tuesday, July 21st. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.62.

AtriCure Stock Performance

Shares of ATRC stock opened at $49.28 on Tuesday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average price of $36.25 and a 200-day moving average price of $31.89. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $49.88. The firm has a market capitalization of $2.51 billion, a PE ratio of 234.68 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 6,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider directly owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This represents a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 44,246 shares of company stock worth $1,691,895. 4.00% of the stock is owned by corporate insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.